Sort
10,766 grants matching “checkpoint inhibitor”
Expanding the tumor antigen landscape and maintaining APCs in a T cell-activating state to restore tumor immunity
$473,680Eduardo Davila · University Of Colorado Denver · R01 · FY2025 · CA
Reversing cancer immunosuppression using attenuated Listeria monocytogenes
$473,641Daniel A Portnoy · University Of California Berkeley · R01 · FY2024 · CA
Reversing cancer immunosuppression using attenuated Listeria monocytogenes
$473,641Daniel A Portnoy · University Of California Berkeley · R01 · FY2025 · CA
FEEDBACK CONTROL OF THE CELL CYCLE
$473,631Harvard University · R37 · FY2001 · GM
Targeting a phosphatidylserine/TAM receptor/PD-L1 axis as a vulnerability in cancer
$473,620Raymond B Birge · Rutgers Biomedical And Health Sciences · R01 · FY2023 · CA
A modular cell therapy platform for controlling immunological tolerance
$473,515Nathan Edward Reticker-Flynn · Stanford University · DP2 · FY2024 · AI
A modular cell therapy platform for controlling immunological tolerance
$473,515Nathan Edward Reticker-Flynn · Stanford University · DP2 · FY2025 · AI
Targeting a phosphatidylserine/TAM receptor/PD-L1 axis as a vulnerability in cancer
$473,506Raymond B Birge · Rutgers Biomedical And Health Sciences · R01 · FY2025 · CA
Understanding the impact of chemotherapy on breast cancer metastasis and immune function in the liver
$473,350Sandra S McAllister · Brigham And Women'S Hospital · R01 · FY2024 · CA
Preclinical Development of First-in-Class NDUFS7 Antagonists for the Treatment of Pancreatic Cancer
$473,270Nouri Neamati · University Of Michigan At Ann Arbor · R01 · FY2022 · CA
An integrated polymeric carrier for subunit cancer vaccines
$473,251Suzie H Pun · University Of Washington · R01 · FY2023 · CA
Re-wiring PDAC Tumor Immunity Through Dendritic Cells
$473,084David G Denardo · Washington University · R01 · FY2025 · CA
Project 4: Therapeutic Targeting of Replication Stress Vulnerabilities in Small Cell Lung Cancer
$472,890Lauren Averett Byers · Ut Southwestern Medical Center · P50 · FY2020 · CA
Targeting Epigenomic Regulators at the Replication Fork in PDAC
$472,850Gwen Lomberk · Medical College Of Wisconsin · R01 · FY2021 · CA
Overcoming the blood-brain barrier with nanoparticle vaccines against gliomas
$472,806Elias Sayour · University Of Florida · R37 · FY2021 · CA
Therapeutic Targeting of Macrophage PI3Kgamma in HNSCC
$472,763Judith A. Varner · University Of California, San Diego · R01 · FY2021 · CA
Elucidating the Role of the Tumor Suppressor KEAP1 in Antitumor Immunity
$472,730Antonio Marzio · Weill Medical Coll Of Cornell Univ · R01 · FY2025 · CA
Project 2: Targeting signaling networks to overcome therapeutic resistance in pancreatic cancer
$472,698Tony R. Hunter · Salk Institute For Biological Studies · P01 · FY2024 · CA
Preclinical Development of First-in-Class NDUFS7 Antagonists for the Treatment of Pancreatic Cancer
$472,491Nouri Neamati · University Of Michigan At Ann Arbor · R01 · FY2025 · CA
Preclinical and clinical characterization of DNMT inhibitors +/- standard chemoimmunotherapy in TNBC
$472,447Liewei Wang · Mayo Clinic Rochester · R01 · FY2025 · CA
PAIRS: Validating telomerase reverse transcriptase (TERT) as an intrinsic vulnerability toward sensitizing cancer to radiation
$472,393Stephen J. Kron · University Of Chicago · R01 · FY2023 · CA
Stroma penetrating and immune modulating nanoparticles for image-guided therapy of pancreatic cancer
$472,215Lily Yang · Emory University · R01 · FY2025 · CA
Cancer Immunotherapy Clinical Trials
$472,182Julius Strauss · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA
Breast and Other Carcinoma Clinical Trials Using Immunotherapies
$472,182Margaret Gatti-Mays · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA
Ascorbic acid as a pharmacologic agent in disease treatment
$472,165Mark A Levine · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2021 · DK